Brief: Shattuck Labs Announces Orphan Drug Designation Granted By The U.S. FDA For Acute Myeloid Leukemia Treatment
10/06/2024 12:35
June 10 (Reuters) - Shattuck Labs Inc STTK.O :
* SHATTUCK LABS ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED BY
THE
U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR SL-172154 FOR THE
TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
Source text for Eikon: ID:nGNX9LFtSb
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health